Sientra to Present at the H.C. Wainwright Bioconnect Virtual Conference
SANTA BARBARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc., (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.
A Pre-recorded presentation will be available on Monday, January 10th at 7:00 am Eastern Time. Interested parties may access a webcast of the presentation on the investor section of the Company’s website at www.Sientra.com.
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Investor Relations Contact